Altimmune, Inc., a biopharmaceutical company, is facing a class action lawsuit following a significant setback in its IMPACT Phase 2b MASH trial. The lawsuit, filed on behalf of shareholders, alleges securities fraud that has led to substantial financial losses for investors between August 10, 2023, and June 25, 2025. The controversy erupted after Altimmune released a press statement on June 26, 2025, revealing that the trial of their drug Pemvidutide failed to achieve statistical significance in reducing fibrosis, a key endpoint. This unexpected outcome was attributed to a higher-than-anticipated placebo response, leaving investors and analysts questioning the company’s prior optimistic projections.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The market reacted swiftly to the news, causing Altimmune’s stock to plummet by 53.2% overnight, from $7.71 to $3.61 per share. This dramatic decline underscores the gravity of the situation for shareholders who had placed their trust in the company’s promising forecasts.
For those who have incurred losses during this period, there is an opportunity to seek recovery. Affected investors are encouraged to visit [this link](https://zlk.com/pslra-1/altimmune-inc-lawsuit-submission-form-2?wire=18) to understand their rights and explore the possibility of joining the class action. Participation comes with no cost or obligation.
The lawsuit is being spearheaded by Levi & Korsinsky LLP, a firm renowned for its prowess in securities litigation. With over two decades of experience and a track record of securing substantial settlements for shareholders, Levi & Korsinsky stands as a formidable advocate for investors seeking justice.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171